The Safety and Efficacy of Second-Generation Basal Insulin Analogues in Adults with Type 2 Diabetes at Risk of Hypoglycemia and Use in Other Special Populations: A Narrative Review

Grants

Funding Acknowledgements

This review received funding from Sanofi. Funding for medical writing support and the journal's rapid service fee was also provided by Sanofi. The funder had the following involvement with the review: funding support to Celia Green, Bioscript Pty Ltd, Australia, who provided literature research and medical writing support; funding for librarian support, with search terms provided by authors; manuscript review, with all final decisions on content determined by the authors.